🔎 Trials Near Me

Home › Endometrial Cancer › Colorado › Aurora

Endometrial Cancer clinical trials in Aurora, CO

15 studies for Endometrial Cancer are looking for participants at sites in and around Aurora (within about 30 miles). Open a study to see who can join and how to contact the study team.

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

RecruitingPhase 3
  • UCHealth University of Colorado Hospital, Aurora
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05256225

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RecruitingPhase 2
  • UCHealth University of Colorado Hospital, Aurora
All ages · All sexes · Updated Sep 28, 2026 · NCT05564377

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

RecruitingPhase 3
  • UCHealth University of Colorado Hospital, Aurora
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT07198074

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

RecruitingPhase 2
  • UCHealth University of Colorado Hospital, Aurora
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

RecruitingPhase 1/2
  • University of Colorado Cancer Center, Aurora
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

RecruitingPhase 1
  • University of Colorado Cancer Center, Aurora
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

RecruitingPhase 1/2
  • GSK Investigational Site, Aurora
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07213609

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

RecruitingObservational study
  • University of Colorado, Aurora
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
  • Children's Hospital Colorado, Aurora
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

RecruitingPhase 2
  • University of Colorado, Aurora
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

RecruitingPhase 1/2
  • Research Site, Aurora
Ages 18 to 130 · All sexes · Updated Aug 21, 2026 · NCT05797168

FOG-001 in Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • University of Colorado, Aurora
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

RecruitingPhase 1/2
  • University of Colorado Cancer Center, Aurora
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

RecruitingPhase 1/2
  • University of Colorado Cancer Center, Aurora
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Aurora
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

Endometrial Cancer trials in other cities

Other studies in Aurora

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.